Apogee Therapeutics, Inc. 8-K

What Happened
Apogee Therapeutics, Inc. announced and furnished a press release on March 2, 2026 providing a business update and reporting its financial results for the year ended December 31, 2025. The Earnings Press Release was filed as Exhibit 99.1 to the Form 8‑K, which was signed by CEO Michael Henderson, M.D.

Key Details

• Filing date: March 2, 2026; Item reported: 2.02 (Results of Operations and Financial Condition).
• Subject: Earnings Press Release reporting financial results for the year ended December 31, 2025.
• Exhibit furnished: 99.1 (Earnings Press Release); cover page interactive XBRL included as Exhibit 104.
• Form 8‑K signed and submitted by Michael Henderson, M.D., Chief Executive Officer.

Why It Matters
This filing formally delivers Apogee’s latest annual financial results and business update to investors and the market. The press release (Exhibit 99.1) is the authoritative source for revenue, earnings, cash position, and any operational or clinical updates for 2025 — investors should review that release for the specific financial figures and any commentary on guidance or strategy. The 8‑K makes the information part of Apogee’s SEC record and may affect investor assessments of the company’s performance and near‑term prospects.